NASOPHARYNGEAL CARCINOMA IMMUNOTHERAPY: Current Strategies and Perspectives

被引:0
作者
Smith, Corey [1 ]
Khanna, Rajiv [1 ]
机构
[1] Queensland Inst Med Res, Div Infect Dis & Immunol, Tumour Immunol Lab, Australian Ctr Vaccine Dev, Brisbane, Qld 4006, Australia
来源
NASOPHARYNGEAL CARCINOMA: KEYS FOR TRANSLATIONAL MEDICINE AND BIOLOGY | 2013年 / 778卷
关键词
EPSTEIN-BARR-VIRUS; T-CELL EPITOPES; ANTIGEN-PROCESSING FUNCTION; MEMBRANE-PROTEIN; EBV-SPECIFIC CTL; ADOPTIVE IMMUNOTHERAPY; ENDOGENOUS PRESENTATION; RESPONSES; MEMORY; CD4(+);
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recent success in treating Epstein-Barr virus (EBV)-associated posttransplant lymphoproliferative disorder (PTLD) using cytotoxic T-cell (CTL) based immunotherapy has led to interest in the development of CTL-based immunotherapy to treat other EBV-associated malignancies, including Nasopharyngeal carcinoma (NPC). However unlike PTLD, which arises in immunosuppressed individuals following transplant, NPC can arise in immunocompetent individuals, expresses a limited array of EBV antigens that are poorly immunogenic, and appear to suppress the function of these T cells either directly or through the expansion of regulatory T cells. There is therefore a unique set of problems that need to be addressed in order to optimise CTL-therapy for the effective treatment of NPC.
引用
收藏
页码:173 / 186
页数:14
相关论文
共 64 条
[1]   Human CD8+ T cell responses to EBV EBNA1:: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing [J].
Blake, N ;
Lee, S ;
Redchenko, I ;
Thomas, W ;
Steven, N ;
Leese, A ;
Steigerwald-Mullen, P ;
Kurilla, MG ;
Frappier, L ;
Rickinson, A .
IMMUNITY, 1997, 7 (06) :791-802
[2]   Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer [J].
Bollard, Catherine M. ;
Gottschalk, Stephen ;
Leen, Ann M. ;
Weiss, Heidi ;
Straathof, Karin C. ;
Carrum, George ;
Khalil, Mariam ;
Wu, Meng-fen ;
Huls, M. Helen ;
Chang, Chung-Che ;
Gresik, M. Victoria ;
Gee, Adrian P. ;
Brenner, Malcolm K. ;
Rooney, Cliona M. ;
Heslop, Helen E. .
BLOOD, 2007, 110 (08) :2838-2845
[3]  
Chia WK, 2011, ANN ONCOL
[4]   Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma [J].
Chua, D ;
Huang, J ;
Zheng, BJ ;
Lau, SY ;
Luk, W ;
Kwong, DLW ;
Sham, JST ;
Moss, D ;
Yuen, KY ;
Im, SWK ;
Ng, MH .
INTERNATIONAL JOURNAL OF CANCER, 2001, 94 (01) :73-80
[5]   Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes [J].
Comoli, P ;
Pedrazzoli, P ;
Maccario, R ;
Basso, S ;
Carminati, O ;
Labirio, M ;
Schiavo, R ;
Secondino, S ;
Frasson, C ;
Perotti, C ;
Moroni, M ;
Locatelli, F ;
Siena, S .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (35) :8942-8949
[6]   Therapeutic LMP1 polyepitope vaccine for EBV-assolciated Hodgkin disease and nasopharyngeal carcinoma [J].
Duraiswamy, J ;
Sherritt, M ;
Thomson, S ;
Tellam, J ;
Cooper, L ;
Connolly, G ;
Bharadwaj, M ;
Khanna, R .
BLOOD, 2003, 101 (08) :3150-3156
[7]   Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients [J].
Gandhi, Maher K. ;
Lambley, Eleanore ;
Duraiswamy, Jaikumar ;
Dua, Ujjwal ;
Smith, Corey ;
Elliott, Suzanne ;
Gill, Devinder ;
Marlton, Paula ;
Seymour, John ;
Khanna, Rajiv .
BLOOD, 2006, 108 (07) :2280-2289
[8]  
Gattinoni L, 2005, J CLIN INVEST, V115, P1616, DOI 10.1172/JCI24480
[9]   Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells [J].
Gattinoni, L ;
Finkelstein, SE ;
Klebanoff, CA ;
Antony, PA ;
Palmer, DC ;
Spiess, PJ ;
Hwang, LN ;
Yu, ZY ;
Wrzesinski, C ;
Heimann, DM ;
Surh, CD ;
Rosenberg, SA ;
Restifo, NP .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (07) :907-912
[10]   Adoptive immunotherapy for cancer: building on success [J].
Gattinoni, L ;
Powell, DJ ;
Rosenberg, SA ;
Restifo, NP .
NATURE REVIEWS IMMUNOLOGY, 2006, 6 (05) :383-393